Compare Aurora Cannabis Inc (ACB) vs Tesla, Inc. (TSLA) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

Tesla (TSLA) trades at $395.04, down 5.89% over the past 24 hours, with a neutral technical signal and mixed earnings history. The stock shows elevated valuation ratios (P/E 369.63, P/S 14.54) against declining profitability margins (net income margin 3.95% in 2025). Recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV model, while Q1 2026 deliveries missed estimates amid competitive pressures.

Outlook remains bifurcated: long-term growth depends on AI and autonomy execution, but near-term risks include softening auto demand and high valuation. Analyst consensus price target is $429.91, implying upside, yet sentiment is cautious with 39.51% buy ratings. Investors face volatility from execution risks and macroeconomic headwinds.